Two proprietary programs, HLP003 for MDD and HLP004 for GAD, have shown rapid, durable efficacy and favorable safety in Phase 2 trials, with HLP003 in Phase 3 and strong patent protection through 2041. The company is well-funded and positioned to address large unmet needs in mental health.Original…
Two proprietary programs, HLP003 for MDD and HLP004 for GAD, have shown rapid, durable efficacy and favorable safety in Phase 2 trials, with HLP003 in Phase 3 and strong patent protection through 2041. The company is well-funded and positioned to address large unmet needs in mental health.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
